Proteomic Innovation

“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.”  Dr. Greg Critchfield, CEO


Sera Prognostics to Present at 27th Annual Piper Jaffray Healthcare Conference

Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the Piper Jaffray Healthcare Conference . Dr. Critchfield’s presentation will take place at 10:30 AM ET on Wednesday, December 2, 2015 at the Lotte New York Palace Hotel in New York, NY. Read More >

Sera Prognostics Announces Early Limited Commercial Access of its PreTRM™ Test

Sera Prognostics, Inc., a women’s healthcare company, today announced a program for early limited commercial access to PreTRM™, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman’s risk of preterm birth. Read More >

Bill & Melinda Gates Foundation Has Agreed to Join Series B Financing

Sera Prognostics announced that the Bill & Melinda Gates Foundation has agreed to join the Company’s Series B financing, which will bring the total transaction to $25 million. Read More >

Our Goals

Providing AN Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 11.4% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM™ Test for Risk Management.